Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021
Introduction: The purpose of this study was to characterize hepatitis C virus screening and treatment access experiences among people in treatment for opioid use disorder in Arizona during COVID-19. Methods: Arizonans receiving treatment for opioid use disorder from methadone clinics and buprenorphi...
Main Authors: | Beth E. Meyerson, PhD, Danielle M. Russell, MS, Missy Downer, BS, Amirah Alfar, Irene Garnett, MLIS, John Lowther, Rebecca Lutz, Arlene Mahoney, BSW, Julie Moore, Greg Nuñez, Savannah Samorano, AA, Benjamin R. Brady, DrPH, Keith G. Bentele, PhD, Brenda Granillo, DBH |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | AJPM Focus |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2773065422000451 |
Similar Items
-
Hepatitis C virus quantification in serum and saliva of HCV-infected patients
by: Gisele Barreto Lopes Menezes, et al.
Published: (2012-08-01) -
Diagnostic accuracy of a new commercially available HCV-antigen test
by: Marta Monari, et al.
Published: (2010-03-01) -
The Distribution of Hepatitis C Virus (HCV) Genotypes in 59 HCV Infected Patients: A Multicenter Study
by: Emine SÖNMEZ, et al.
Published: (1996-06-01) -
Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
by: Beth E Meyerson, et al.
Published: (2022-01-01) -
HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
by: Rujipat Wasitthankasem, et al.
Published: (2017-11-01)